STERIS plc (NYSE:STE) Shares Sold by Carderock Capital Management Inc.

Carderock Capital Management Inc. lessened its position in shares of STERIS plc (NYSE:STE) by 7.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 29,588 shares of the medical equipment provider’s stock after selling 2,341 shares during the quarter. Carderock Capital Management Inc.’s holdings in STERIS were worth $7,176,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Central Pacific Bank Trust Division acquired a new position in shares of STERIS in the 3rd quarter valued at $28,000. J.Safra Asset Management Corp increased its position in shares of STERIS by 77.9% during the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 53 shares during the last quarter. Quent Capital LLC raised its stake in shares of STERIS by 112.7% in the 1st quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 71 shares during the period. Headlands Technologies LLC acquired a new position in shares of STERIS in the 1st quarter worth approximately $36,000. Finally, Versant Capital Management Inc boosted its position in shares of STERIS by 2,262.5% during the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 181 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Stephens restated an “overweight” rating and set a $260.00 price target on shares of STERIS in a research note on Wednesday, August 7th. StockNews.com raised shares of STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Thursday, August 8th. KeyCorp increased their target price on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Finally, JMP Securities restated a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research note on Wednesday, August 7th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and a consensus price target of $246.00.

STERIS Stock Down 0.3 %

Shares of STERIS stock opened at $225.99 on Thursday. The company has a quick ratio of 1.49, a current ratio of 2.33 and a debt-to-equity ratio of 0.35. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24. The company has a market capitalization of $22.34 billion, a P/E ratio of 59.16 and a beta of 0.84. The company has a 50 day moving average of $236.16 and a 200 day moving average of $225.91.

STERIS (NYSE:STE) last issued its earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.16. The firm had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The company’s revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.00 earnings per share. As a group, research analysts forecast that STERIS plc will post 9.06 EPS for the current fiscal year.

STERIS Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, September 5th were issued a dividend of $0.57 per share. The ex-dividend date was Thursday, September 5th. This represents a $2.28 dividend on an annualized basis and a yield of 1.01%. This is a boost from STERIS’s previous quarterly dividend of $0.52. STERIS’s dividend payout ratio (DPR) is presently 59.69%.

Insider Transactions at STERIS

In related news, Director Christopher S. Holland sold 473 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the transaction, the director now directly owns 582 shares of the company’s stock, valued at $139,493.76. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares in the company, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now owns 582 shares in the company, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.